{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:33:22Z","timestamp":1787002402890,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03654-9","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:47:44Z","timestamp":1786956464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Assessment of Healthcare Resource Utilization-Defined Manic and Depressive Events Among Patients with Bipolar I Disorder Treated with Cariprazine Versus Aripiprazole"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousam","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Zanardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-1796","authenticated-orcid":false,"given":"Huy-Binh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4543-6880","authenticated-orcid":false,"given":"Eric J.","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Aronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"10265","key":"3654_CR1","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","volume":"396","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841\u201356.","journal-title":"Lancet"},{"key":"3654_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders, 5th Edition: DSM-5","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition: DSM-5. Washington, DC: American Psychiatric Publishing; 2013."},{"key":"3654_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jpsychires.2016.10.003","volume":"84","author":"C Blanco","year":"2017","unstructured":"Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the National Epidemiologic Survey on alcohol and related conditions\u2014III. J Psychiatr Res. 2017;84:310\u20137.","journal-title":"J Psychiatr Res"},{"key":"3654_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2017.09.011","volume":"226","author":"M Cloutier","year":"2018","unstructured":"Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45\u201351.","journal-title":"J Affect Disord"},{"issue":"6","key":"3654_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1034\/j.1399-5618.2002.01148.x","volume":"4","author":"L Bryant-Comstock","year":"2002","unstructured":"Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4(6):398\u2013405.","journal-title":"Bipolar Disord"},{"issue":"6","key":"3654_CR6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","volume":"59","author":"LL Judd","year":"2002","unstructured":"Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"3654_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.8","volume":"4","author":"E Vieta","year":"2018","unstructured":"Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3654_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/wps.20997","volume":"21","author":"RS McIntyre","year":"2022","unstructured":"McIntyre RS, Alda M, Baldessarini RJ, et al. The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management. World Psychiatry. 2022;21(3):364\u201387.","journal-title":"World Psychiatry"},{"issue":"5","key":"3654_CR9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1399-5618.2007.00553.x","volume":"10","author":"HM Valtonen","year":"2008","unstructured":"Valtonen HM, Suominen K, Haukka J, et al. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord. 2008;10(5):588\u201396.","journal-title":"Bipolar Disord"},{"key":"3654_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jad.2014.09.026","volume":"172","author":"RS McIntyre","year":"2015","unstructured":"McIntyre RS, Soczynska JK, Cha DS, et al. The prevalence and illness characteristics of DSM-5-defined \u201cmixed feature specifier\u201d in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2015;172:259\u201364.","journal-title":"J Affect Disord"},{"issue":"2\u20133","key":"3654_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jad.2005.12.049","volume":"91","author":"J Bal\u00e1zs","year":"2006","unstructured":"Bal\u00e1zs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord. 2006;91(2\u20133):133\u20138.","journal-title":"J Affect Disord"},{"issue":"2","key":"3654_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1176\/appi.ajp.2008.08050746","volume":"166","author":"JF Goldberg","year":"2009","unstructured":"Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009;166(2):173\u201381.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"3654_CR13","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.4088\/JCP.09r05259gre","volume":"71","author":"G Salvadore","year":"2010","unstructured":"Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry. 2010;71(11):1488\u2013501.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"3654_CR14","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1176\/appi.ajp.160.12.2099","volume":"160","author":"M Tohen","year":"2003","unstructured":"Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099\u2013107.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"3654_CR15","doi-asserted-by":"publisher","first-page":"19m12986","DOI":"10.4088\/JCP.19m12896","volume":"81","author":"G Maccariello","year":"2020","unstructured":"Maccariello G, Barbuti M, Vannucchi G, et al. Predictors of depressive switch in patients with bipolar I disorder who initiated or changed pharmacologic treatment for mania or mixed-mania: a prospective observational study. J Clin Psychiatry. 2020;81(4):19m12986.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"3654_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0165-0327(02)00265-3","volume":"78","author":"R Bottlender","year":"2004","unstructured":"Bottlender R, Sato T, Kleindienst N, Strauss A, Moller HJ. Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. J Affect Disord. 2004;78(2):149\u201352.","journal-title":"J Affect Disord"},{"issue":"10","key":"3654_CR17","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1176\/appi.ajp.159.10.1711","volume":"159","author":"M Maj","year":"2002","unstructured":"Maj M, Pirozzi R, Magliano L, Bartoli L. The prognostic significance of \u201cswitching\u201d in patients with bipolar disorder: a 10-year prospective follow-up study. Am J Psychiatry. 2002;159(10):1711\u20137.","journal-title":"Am J Psychiatry"},{"key":"3654_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jpsychires.2015.04.014","volume":"66\u201367","author":"T Niitsu","year":"2015","unstructured":"Niitsu T, Fabbri C, Serretti A. Predictors of switch from depression to mania in bipolar disorder. J Psychiatr Res. 2015;66\u201367:45\u201353.","journal-title":"J Psychiatr Res"},{"issue":"9878","key":"3654_CR19","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","volume":"381","author":"JR Geddes","year":"2013","unstructured":"Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672\u201382.","journal-title":"Lancet"},{"issue":"2","key":"3654_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170.","journal-title":"Bipolar Disord"},{"issue":"4","key":"3654_CR21","first-page":"344","volume":"21","author":"K Keramatian","year":"2023","unstructured":"Keramatian K, Chithra NK, Yatham LN. The CANMAT and ISBD guidelines for the treatment of bipolar disorder: summary and a 2023 update of evidence. Focus (Am Psychiatr Publ). 2023;21(4):344\u201353.","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"5","key":"3654_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/hup.2326","volume":"28","author":"W Chen","year":"2013","unstructured":"Chen W, Deveaugh-Geiss AM, Palmer L, Princic N, Chen YT. Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA. Hum Psychopharmacol. 2013;28(5):428\u201337.","journal-title":"Hum Psychopharmacol"},{"key":"3654_CR23","unstructured":"VRAYLAR\u00ae (cariprazine). Full Prescribing Information. North Chicago, IL: AbbVie, Inc.; 2024."},{"key":"3654_CR24","unstructured":"ABILIFY\u00ae (aripiprazole). Full Prescribing Information. Otsuka Pharmaceutical Co, Ltd.; 2024."},{"key":"3654_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2023.03.009","volume":"72","author":"KN Fountoulakis","year":"2023","unstructured":"Fountoulakis KN, Ioannou M, Tohen M, Haarman BCM, Zarate CA Jr. Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: a hypothesis based on data. Eur Neuropsychopharmacol. 2023;72:30\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"3654_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","volume":"18","author":"JA Lieberman","year":"2004","unstructured":"Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251\u201367.","journal-title":"CNS Drugs"},{"key":"3654_CR27","volume-title":"NDA 21-436\/S-002 approval letter","author":"US Food and Drug Administration","year":"2004","unstructured":"US Food and Drug Administration. NDA 21-436\/S-002 approval letter. Rockville, MD: US Department of Health and Human Services; 2004."},{"key":"3654_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.781946","volume":"12","author":"P Mohr","year":"2021","unstructured":"Mohr P, Masopust J, Kope\u010dek M. Dopamine receptor partial agonists: do they differ in their clinical efficacy? Front Psychiatry. 2021;12:781946.","journal-title":"Front Psychiatry"},{"issue":"1","key":"3654_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328\u201340.","journal-title":"J Pharmacol Exp Ther"},{"issue":"19-20","key":"3654_CR30","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","volume":"233","author":"RR Girgis","year":"2016","unstructured":"Girgis RR, Slifstein M, D\u2019Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. 2016;233(19\u201320):3503\u201312.","journal-title":"Psychopharmacology"},{"issue":"6","key":"3654_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","volume":"59","author":"I Gyertyan","year":"2011","unstructured":"Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925\u201335.","journal-title":"Neurochem Int"},{"key":"3654_CR32","unstructured":"IQVIA. Fact Sheet: IQVIA PharMetrics Plus. Available at: https:\/\/www.iqvia.com\/locations\/united-states\/library\/fact-sheets\/iqvia-pharmetrics-plus. Accessed October 31, 2024."},{"key":"3654_CR33","unstructured":"GovInfo.gov. Public Law 104 - 191 - Health Insurance Portability and Accountability Act of 1996. Available at: https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-104publ191\/pdf\/PLAW-104publ191.pdf. Accessed August 26, 2024."},{"issue":"1","key":"3654_CR34","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/13696998.2022.2120264","volume":"25","author":"RS McIntyre","year":"2022","unstructured":"McIntyre RS, Higa S, Doan QV, et al. Place of care and costs associated with acute episodes and remission in bipolar I disorder. J Med Econ. 2022;25(1):1110\u20137.","journal-title":"J Med Econ"},{"issue":"28","key":"3654_CR35","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"11","key":"3654_CR36","volume":"11","author":"N Zareifopoulos","year":"2019","unstructured":"Zareifopoulos N, Panayiotakopoulos G. Treatment options for acute agitation in psychiatric patients: theoretical and empirical evidence. Cureus. 2019;11(11):e6152.","journal-title":"Cureus"},{"issue":"8","key":"3654_CR37","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/pm\/pnac029","volume":"23","author":"J Leung","year":"2022","unstructured":"Leung J, Santo T, Colledge-Frisby S, et al. Mood and anxiety symptoms in persons taking prescription opioids: a systematic review with meta-analyses of longitudinal studies. Pain Med. 2022;23(8):1442\u201356.","journal-title":"Pain Med"},{"key":"3654_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jad.2022.06.086","volume":"313","author":"PO Eseaton","year":"2022","unstructured":"Eseaton PO, Oladunjoye AF, Anugwom G, Onyeaka H, Edigin E, Osiezagha K. Emergency department utilization by patients with Bipolar disorder: a national population-based study. J Affect Disord. 2022;313:232\u20134.","journal-title":"J Affect Disord"},{"key":"3654_CR39","unstructured":"Weiss AJ, Barrett ML, Heslin KC, Stocks C. Trends in emergency department visits involving mental and substance use disorders, 2006\u20132013. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006."},{"key":"3654_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/CEOR.S259338","volume":"12","author":"L Bessonova","year":"2020","unstructured":"Bessonova L, Ogden K, Doane MJ, O\u2019Sullivan AK, Tohen M. The economic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:481\u201397.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"3654_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12991-023-00440-7","volume":"22","author":"C Dembek","year":"2023","unstructured":"Dembek C, Mackie D, Modi K, Zhu Y, Niu X, Grinnell T. The economic and humanistic burden of bipolar disorder in adults in the United States. Ann Gen Psychiatry. 2023;22(1):13.","journal-title":"Ann Gen Psychiatry"},{"issue":"11","key":"3654_CR42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.clinthera.2024.08.003","volume":"46","author":"L Culpepper","year":"2024","unstructured":"Culpepper L, Martin A, Harrington A, Wade SW, Parikh M. A retrospective cross-sectional analysis of the humanistic and economic burden of bipolar I disorder. Clin Ther. 2024;46(11):855\u201364.","journal-title":"Clin Ther"},{"issue":"10","key":"3654_CR43","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.clinthera.2018.08.004","volume":"40","author":"MS Broder","year":"2018","unstructured":"Broder MS, Greene M, Chang E, et al. Health care resource use, costs, and diagnosis patterns in patients with schizophrenia and bipolar disorder: real-world evidence from US claims databases. Clin Ther. 2018;40(10):1670\u201382.","journal-title":"Clin Ther"},{"issue":"1","key":"3654_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40345-023-00322-7","volume":"12","author":"LV Kessing","year":"2024","unstructured":"Kessing LV. Why is lithium [not] the drug of choice for bipolar disorder? A controversy between science and clinical practice. Int J Bipolar Disord. 2024;12(1):3.","journal-title":"Int J Bipolar Disord"},{"issue":"1","key":"3654_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jad.2013.03.007","volume":"148","author":"E Vieta","year":"2013","unstructured":"Vieta E, Valent\u00ed M. Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord. 2013;148(1):28\u201336.","journal-title":"J Affect Disord"},{"issue":"3","key":"3654_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jad.2012.07.038","volume":"144","author":"JM Goikolea","year":"2013","unstructured":"Goikolea JM, Colom F, Torres I, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. J Affect Disord. 2013;144(3):191\u20138.","journal-title":"J Affect Disord"},{"issue":"1-3","key":"3654_CR47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jad.2009.02.007","volume":"118","author":"E Vieta","year":"2009","unstructured":"Vieta E, Angst J, Reed C, Bertsch J, Haro JM, EMBLEM Advisory Board. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM). J Affect Disord. 2009;118(1\u20133):118\u201323.","journal-title":"J Affect Disord"},{"issue":"1","key":"3654_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bdi.12238","volume":"17","author":"S Durgam","year":"2015","unstructured":"Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63\u201375.","journal-title":"Bipolar Disord"},{"key":"3654_CR49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","volume":"174","author":"GS Sachs","year":"2015","unstructured":"Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296\u2013302.","journal-title":"J Affect Disord"},{"issue":"3","key":"3654_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4088\/JCP.14m09081","volume":"76","author":"JR Calabrese","year":"2015","unstructured":"Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284\u201392.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"3654_CR51","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","volume":"173","author":"S Durgam","year":"2016","unstructured":"Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173(3):271\u201381.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"3654_CR52","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bdi.12852","volume":"22","author":"WR Earley","year":"2020","unstructured":"Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020;22(4):372\u201384.","journal-title":"Bipolar Disord"},{"issue":"6","key":"3654_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","volume":"176","author":"W Earley","year":"2019","unstructured":"Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019;176(6):439\u201348.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"3654_CR54","volume":"22","author":"LN Yatham","year":"2020","unstructured":"Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W. Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications. Prim Care Companion CNS Disord. 2020;22(5):24841.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"11","key":"3654_CR55","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.euroneuro.2015.08.020","volume":"25","author":"E Vieta","year":"2015","unstructured":"Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II\/III trials. Eur Neuropsychopharmacol. 2015;25(11):1882\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3654_CR56","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jad.2019.07.020","volume":"257","author":"RS McIntyre","year":"2019","unstructured":"McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J Affect Disord. 2019;257:600\u20136.","journal-title":"J Affect Disord"},{"issue":"4","key":"3654_CR57","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1017\/S1092852919001287","volume":"25","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr. 2020;25(4):502\u201310.","journal-title":"CNS Spectr"},{"key":"3654_CR58","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jad.2024.08.119","volume":"366","author":"E Vieta","year":"2024","unstructured":"Vieta E, McIntyre RS, Yu J, Aronin LC, Kramer K, Nguyen HB. Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: post hoc analysis of pooled randomized controlled trial data. J Affect Disord. 2024;366:136\u201345.","journal-title":"J Affect Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03654-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03654-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03654-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:01:55Z","timestamp":1787000515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03654-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":58,"alternative-id":["3654"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03654-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roger S. McIntyre has received research grant support from the Canadian Institute of Health Research (CIHR), Global Alliance for Chronic Diseases (GACD), Milken Institute, and the National Natural Science Foundation of China (NSFC); has received speaker\/consultation fees from AbbVie, Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Janssen, Kris, Intra-Cellular, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, NewBridge Pharmaceuticals, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris; and is a CEO of Braxia Scientific Corp. Roger S. McIntyre is also an Editorial Board member and Section Editor of\n                      Advances in Therapy\n                      . He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mousam Parikh, Huy-Binh Nguyen, Eric J. Christopher, Lauren C. Aronin, and Jamie Ta are employees of AbbVie, which funded the study, and may hold stock. Enrico Zanardo, Fran\u00e7ois Lalibert\u00e9, Kaixin Zhang, and Sophie Ma are employees of Analysis Group Inc., which was funded by AbbVie to perform this analysis.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from ethics committee approval and institutional review because it is a retrospective analysis that used anonymized and de-identified data certified as fully compliant with the United States patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}